Fig. 1

Deep sequencing systematically determined the differential expression of lncRNAs and mRNAs in colon cancer cells upon TP53 overexpression, TP53 R175H mutation or TP53 R175H mutation. (a, b) Principal Component Analysis (PCA) of lncRNA and mRNA expression of the four groups of DLD1 colon cancer cell lines. Sample variability is the driving force for PCA to extract principal components, directly determining the effectiveness and reliability of downstream analyses. (c) Western blotting showed the protein expression of TP53 and GAPDH in the DLD1 cells of TP53-null control, TP53-WT, TP53-R175H and TP53-R175P. (d) The flowchart of the study design and data analysis pipeline. Three cell group pairs, including TP53-null vs TP53-WT, TP53-R175H vs TP53-WT, and TP53-R175P vs TP53-WT, were analyzed.